Palmitoylethanolamide-Based Endocannabinoid Therapy

Neuroinflammation represents a critical pathological hallmark across multiple neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The endocannabinoid system has emerged as a pivotal regulatory network controlling neuroinflammatory responses through complex interactions between endogenous lipid mediators, their receptors, and downstream signaling cascades. Palmitoylethanolamide (PEA), an endogenous fatty acid ethanolamide, represents a particularly promising therapeutic target due to its dual role as both an endocannabinoid-related compound and a direct modulator of peroxisome proliferator-activated receptor alpha (PPARA).

...

Background and Rationale

Neuroinflammation represents a critical pathological hallmark across multiple neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The endocannabinoid system has emerged as a pivotal regulatory network controlling neuroinflammatory responses through complex interactions between endogenous lipid mediators, their receptors, and downstream signaling cascades. Palmitoylethanolamide (PEA), an endogenous fatty acid ethanolamide, represents a particularly promising therapeutic target due to its dual role as both an endocannabinoid-related compound and a direct modulator of peroxisome proliferator-activated receptor alpha (PPARA).

PEA was first identified in the 1950s and has since been recognized as a member of the N-acylethanolamine family, alongside the classical endocannabinoid anandamide. Unlike traditional cannabinoids, PEA exhibits minimal direct binding affinity for CB1 and CB2 receptors but exerts profound anti-inflammatory and neuroprotective effects through alternative molecular mechanisms. The compound is synthesized on-demand from membrane phospholipids via N-acyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) and is primarily degraded by fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA).

The therapeutic potential of PEA-based interventions stems from growing evidence that endocannabinoid system dysfunction contributes significantly to neuroinflammatory pathology. Microglial activation, characterized by morphological transformation, cytokine release, and altered phagocytic activity, represents a central component of neuroinflammation that can be therapeutically targeted through endocannabinoid modulation. The PPARA-mediated pathway offers a unique mechanism for achieving anti-inflammatory effects while avoiding the psychoactive side effects associated with CB1 receptor activation.

Proposed Mechanism

The proposed mechanism centers on PEA's ability to activate PPARA, a nuclear receptor transcription factor that serves as a master regulator of lipid metabolism and inflammatory gene expression. Upon PEA binding, PPARA undergoes conformational changes that promote its translocation to the nucleus, where it heterodimerizes with retinoid X receptor (RXR). This PPARA-RXR complex subsequently binds to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes, initiating transcriptional programs that suppress pro-inflammatory mediator production.

At the cellular level, PEA-mediated PPARA activation in microglia leads to several key anti-inflammatory outcomes. First, it suppresses the transcription of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), and interleukin-6 (IL-6) through interference with nuclear factor-kappa B (NF-κB) signaling. Simultaneously, PPARA activation enhances the expression of anti-inflammatory mediators such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), shifting the microglial phenotype from a pro-inflammatory M1 state toward a neuroprotective M2 state.

The mechanism also involves modulation of arachidonic acid metabolism through PPARA-mediated transcriptional control of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) expression. This results in reduced production of pro-inflammatory prostaglandins and leukotrienes while potentially enhancing the synthesis of specialized pro-resolving mediators that actively promote inflammation resolution. Additionally, PEA may indirectly enhance endocannabinoid signaling through the "entourage effect," wherein it inhibits FAAH activity, thereby increasing local concentrations of anandamide and prolonging endocannabinoid-mediated anti-inflammatory effects.

Supporting Evidence

Multiple preclinical studies have demonstrated PEA's neuroprotective efficacy across various neurodegeneration models. Esposito et al. (2012) showed that PEA treatment significantly reduced neuroinflammation and neuronal loss in a mouse model of Alzheimer's disease, with effects mediated through PPARA activation. The study demonstrated decreased microglial activation markers and reduced amyloid-beta plaque burden following chronic PEA administration.

In Parkinson's disease models, Calabrese et al. (2015) reported that PEA treatment protected dopaminergic neurons from MPTP-induced toxicity through mechanisms involving both PPARA activation and modulation of neuroinflammatory responses. The protective effects were abolished by PPARA antagonists, confirming the central role of this nuclear receptor in PEA's therapeutic mechanism.

Clinical evidence, though limited, supports PEA's therapeutic potential. A randomized controlled trial by Impellizzeri et al. (2013) demonstrated that PEA supplementation reduced inflammatory markers and improved neurological outcomes in patients with traumatic brain injury. Additionally, observational studies in multiple sclerosis patients have reported improvements in fatigue and quality of life measures following PEA treatment, though larger controlled trials are needed to establish definitive clinical efficacy.

Recent transcriptomic analyses have provided molecular-level support for PEA's anti-inflammatory mechanism. D'Agostino et al. (2019) used RNA sequencing to demonstrate that PEA treatment in LPS-stimulated microglia results in widespread changes in gene expression profiles consistent with PPARA activation, including upregulation of fatty acid oxidation genes and downregulation of inflammatory mediator genes.

Experimental Approach

Validating this therapeutic hypothesis requires a multi-faceted experimental approach combining in vitro, in vivo, and clinical studies. Primary microglial cultures from rodent or human sources would serve as initial screening platforms to establish dose-response relationships for PEA's anti-inflammatory effects. These studies should employ PPARA knockout or knockdown approaches to confirm receptor-dependent mechanisms, alongside transcriptomic and proteomic analyses to map downstream signaling pathways comprehensively.

In vivo validation would utilize established mouse models of neurodegeneration, including APP/PS1 transgenic mice for Alzheimer's disease, MPTP or alpha-synuclein overexpression models for Parkinson's disease, and SOD1 mutant mice for amyotrophic lateral sclerosis. Treatment protocols should examine both preventive and therapeutic administration regimens, with outcomes assessed through behavioral testing, neuroimaging, histopathological analysis, and biochemical markers of neuroinflammation.

Advanced techniques including two-photon microscopy for real-time microglial dynamics, single-cell RNA sequencing for cellular heterogeneity analysis, and mass spectrometry-based lipidomics for endocannabinoid profiling would provide mechanistic insights. Biomarker development studies should identify peripheral inflammatory markers that correlate with central nervous system PPARA activation to enable clinical monitoring.

Clinical Implications

Successful development of PEA-based neuroinflammation therapy could address significant unmet medical needs across multiple neurodegenerative conditions. The compound's excellent safety profile, established through decades of use as a nutritional supplement, facilitates clinical translation compared to novel synthetic compounds requiring extensive toxicology studies.

PEA therapy could be particularly valuable as an adjunctive treatment combined with existing disease-modifying therapies. For Alzheimer's disease, PEA might enhance the efficacy of anti-amyloid or anti-tau treatments by addressing the neuroinflammatory component of pathogenesis. In Parkinson's disease, combination with dopamine replacement or neuroprotective agents could provide synergistic benefits.

The therapeutic approach also offers potential for personalized medicine applications. Genetic polymorphisms affecting PPARA expression or endocannabinoid metabolism could serve as biomarkers for treatment response prediction. Additionally, peripheral inflammatory profiling might guide optimal dosing and treatment timing.

Challenges and Limitations

Several challenges must be addressed for successful therapeutic development. PEA's poor oral bioavailability and rapid metabolism necessitate advanced formulation strategies or novel delivery systems to achieve therapeutically relevant brain concentrations. Micronized formulations and lipid-based delivery systems have shown promise but require optimization for neurological applications.

The complexity of neuroinflammation, involving multiple cell types and signaling pathways, raises questions about whether PPARA-mediated mechanisms alone provide sufficient therapeutic benefit. Competing hypotheses suggest that combination approaches targeting multiple inflammatory pathways may be necessary for optimal outcomes.

Translational challenges include the species differences in endocannabinoid system function and the difficulty of establishing pharmacodynamic biomarkers for central nervous system PPARA activation. Additionally, the chronic nature of neurodegenerative diseases requires long-term safety data for PEA treatment, particularly regarding potential effects on lipid metabolism and hormone regulation.

Mermaid diagram (expand to render)

PEA Pharmacology and Pharmacokinetics

Palmitoylethanolamide presents a complex pharmacokinetic profile that has driven substantial formulation innovation over the past decade. Following oral administration, native crystalline PEA demonstrates poor bioavailability (estimated 5–10%) due to its low aqueous solubility and susceptibility to first-pass intestinal metabolism. The compound has a calculated logP of approximately 4.1, indicating moderate lipophilicity consistent with passive membrane permeation but limited dissolution in the gastrointestinal milieu.

Two proprietary micronization technologies have substantially improved oral bioavailability: ultramicronized PEA (umPEA, Normast/Epitech), produced by jet milling to particle diameters of 6–10 µm, and the PeaPure formulation produced by co-micronization with excipients. Pharmacokinetic studies with umPEA demonstrate approximately 2-fold improvement in Cmax and AUC versus native crystalline PEA ^[1]. The compound achieves peak plasma concentrations (Tmax) between 1.5–4 hours post-dosing, with a plasma elimination half-life of approximately 2 hours reflecting rapid tissue distribution.

Blood-brain barrier penetration is facilitated by PEA's lipophilicity and small molecular weight (299.49 Da). Microdialysis studies in rodents following systemic PEA administration demonstrate dose-proportional increases in cortical and striatal PEA concentrations, suggesting adequate CNS penetration at therapeutically relevant plasma concentrations ^[2]. Brain tissue concentrations typically reach 15–25% of corresponding plasma concentrations within 60 minutes of peak plasma levels. Distribution is highest in adipose tissue and brain, with lower concentrations in muscle and plasma.

Metabolic clearance of PEA is mediated primarily by two enzymes: fatty acid amide hydrolase (FAAH), which cleaves the amide bond to yield palmitic acid and ethanolamine, and N-acylethanolamine acid amidase (NAAA), which preferentially degrades PEA at lysosomal pH. NAAA shows approximately 30-fold substrate preference for PEA over anandamide, making it a particularly relevant target for understanding PEA-specific regulation ^[3]. The complementary activities of FAAH and NAAA ensure rapid clearance, necessitating multiple daily dosing (typically 300–600 mg twice daily) to maintain therapeutic tissue concentrations. Clinical pharmacokinetic analyses suggest that steady-state plasma concentrations following 600 mg twice-daily umPEA reach approximately 2–3 ng/mL, well above the estimated EC50 for PPARA activation in cellular systems.

PPARA Transcriptional Network and Coactivators

Peroxisome proliferator-activated receptor alpha (PPARA, NR1C1) functions as a ligand-activated nuclear receptor that orchestrates a broad transcriptional program regulating lipid catabolism, mitochondrial biogenesis, and inflammatory gene suppression. PPARA belongs to the nuclear receptor superfamily alongside PPARγ (NR1C3) and PPARδ (NR1C2), with distinct tissue distributions and target gene profiles. PPARA predominates in metabolically active tissues with high fatty acid oxidation rates—liver, heart, skeletal muscle, and importantly, neurons and activated microglia ^[4].

The receptor's architecture features four functional domains: the N-terminal A/B domain (ligand-independent activation, AF-1), the DNA-binding domain (DBD, C domain) containing two zinc fingers that contact PPRE half-sites, the hinge region (D domain) mediating nuclear localization, and the C-terminal ligand-binding domain (LBD, E domain). Crystal structures of the PPARA LBD reveal a large hydrophobic binding pocket (~1300 Å³) capable of accommodating diverse fatty acid ligands including long-chain fatty acids (oleic acid, palmitic acid), eicosanoids (15-HETE, 8-HETE), and synthetic agonists (GW7647, WY-14643) ^[5]. PEA docks within this binding pocket with an estimated Kd of approximately 100–300 nM, weaker than dedicated PPARA agonists but sufficient for physiologically relevant transcriptional activation.

Active PPARA dimerizes obligatorily with retinoid X receptor (RXR) to form a heterodimer that binds peroxisome proliferator response elements (PPREs). Canonical PPREs consist of two direct hexanucleotide repeats (AGG/TTCA) separated by one nucleotide (DR-1 motif), positioned in the promoters of target genes ^[6]. Following ligand binding and dimerization, the PPARA-RXR complex recruits coactivator complexes including the p160/SRC family (SRC-1/NCoA-1, SRC-2/TIF2, SRC-3/AIB1) and the CREB-binding protein/p300 (CBP/p300) acetyltransferases, facilitating chromatin remodeling and RNA polymerase II recruitment.

The PPARA-PGC-1α axis represents a critical regulatory node integrating metabolic and inflammatory signaling. PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1 alpha, encoded by PPARGC1A) functions as a transcriptional coactivator that docks with the AF-2 helix of activated PPARA, dramatically amplifying target gene transcription ^[7]. PGC-1α activity is regulated post-translationally: SIRT1-mediated deacetylation activates PGC-1α, while GCN5 acetyltransferase promotes its cytoplasmic sequestration and degradation. This creates the critical link between NAD+ availability (SIRT1 activity) and mitochondrial biogenesis (PGC-1α-driven transcription).

The anti-inflammatory mechanism of PPARA activation involves direct interference with NF-κB signaling through multiple mechanisms. First, PPARA activation promotes transcription of IκBα, the primary inhibitor of NF-κB nuclear translocation. Second, the PPARA-RXR heterodimer physically interacts with the NF-κB p65 subunit, preventing its DNA binding through competitive sequestration of shared transcriptional coactivators ^[7]. Third, PPARA activation induces expression of PPAR-γ coactivator-1β (PGC-1β), which represses inflammatory gene induction independently. These convergent mechanisms explain PEA-PPARA's potent anti-inflammatory effects even at gene promoters lacking canonical PPREs.

Microglial Polarization States and PEA-PPARA Effects

The traditional binary M1/M2 classification of microglial activation, while pedagogically useful, fails to capture the continuous spectrum of microglial states observed in neurodegenerative disease. Single-cell RNA sequencing studies have revealed that microglia adopt numerous distinct transcriptional states in the context of neurodegeneration, with the Disease-Associated Microglia (DAM) signature representing a critical transition state with therapeutic implications ^[8].

Homeostatic microglia are characterized by high expression of P2RY12, TMEM119, CX3CR1, and SALL1—genes that define the microglia-specific signature and maintain surveilling functions. In Alzheimer's disease, microglia transition from homeostatic states through intermediate DAM1 states (characterized by P2RY12 downregulation and TYROBP upregulation) to DAM2 states marked by TREM2, APOE, LPL, CST7, and CLEC7A upregulation. The DAM2 transition is critically dependent on TREM2 signaling, as TREM2-deficient mice show arrested transition at the DAM1 stage ^[8].

PPARA activation by PEA profoundly influences microglial state transitions through several mechanisms. PPARA target genes include APOE (a central DAM2 marker and lipid transport regulator), LPL (required for lipid droplet clearance and amyloid phagocytosis), and CPT1A (carnitine palmitoyltransferase 1A, promoting fatty acid oxidation in metabolically activated DAM microglia). This transcriptional overlap suggests that PEA-mediated PPARA activation may facilitate the transition from homeostatic to neuroprotective DAM states ^[9].

Aging represents a critical variable in microglial biology. Aged microglia demonstrate reduced homeostatic gene expression, elevated senescence markers (p21/CDKN1A, p16/CDKN2A), accumulation of lipid droplets, and heightened inflammatory reactivity termed "microglial senescence" or "inflammaging." Transcriptomic profiling of aged versus young microglia reveals that aged microglia show reduced PPARA expression, potentially explaining the impaired anti-inflammatory responses observed with aging ^[10]. PEA treatment in aged mice has been shown to restore PPARA expression and reduce microglial senescence markers, suggesting direct therapeutic relevance.

Microglial morphology serves as a functional indicator of activation state: homeostatic microglia display highly ramified processes enabling continuous parenchymal surveillance, while activated microglia show process retraction and amoeboid morphology. PEA treatment in LPS-stimulated primary microglia restores process ramification—quantified by Sholl analysis—through PPARA-dependent mechanisms, supporting the functional significance of PPARA activation in maintaining microglial homeostatic morphology ^[1]. Calcium signaling represents another mechanistic connection: PPARA activation modulates store-operated calcium entry (SOCE) in microglia through STIM1/Orai1 pathway regulation, potentially influencing process dynamics and phagocytic capacity.

Synergistic Combinations and Future Therapeutic Directions

The most clinically advanced combination strategy pairs PEA with luteolin, a flavonoid antioxidant that activates Nrf2 signaling, in the co-ultra PEALut formulation (Glialia, Epitech). This combination demonstrates synergistic anti-inflammatory effects in LPS-stimulated mast cells and microglia, attributable to complementary mechanisms: PPARA activation (PEA) reducing inflammatory gene transcription while Nrf2 activation (luteolin) enhances antioxidant defense and suppresses oxidative inflammatory amplification ^[11]. Clinical trials of PEALut in patients with multiple sclerosis demonstrated significant improvements in fatigue and quality-of-life measures compared to either component alone.

Mechanistic synergies also exist with GLP-1 receptor agonists (liraglutide, semaglutide), which activate PPARA in neurons and astrocytes as part of their neuroprotective mechanism. The endocannabinoid-incretine axis represents a bidirectional regulatory system: GLP-1 receptor signaling increases 2-AG synthesis, while endocannabinoid system activation enhances GLP-1 secretion from intestinal L-cells. Combined PEA + liraglutide treatment in 5xFAD mice shows additive reduction in amyloid burden and neuroinflammation compared to either treatment alone ^[12].

The ketogenic diet (KD) represents a metabolic intervention with mechanistic overlap with PEA-PPARA therapy. KD increases plasma and tissue concentrations of β-hydroxybutyrate and acetoacetate, which serve as endogenous PPARA ligands activating hepatic and neuronal PPARA ^[13]. The combination of umPEA supplementation during KD intervention has been explored in preclinical epilepsy models, where synergistic seizure reduction was observed alongside enhanced mitochondrial biogenesis. This metabolic synergy suggests a broader therapeutic framework targeting PPARA as a metabolic-inflammatory switch in neurodegeneration.

Next-generation delivery strategies include PLGA nanoparticle encapsulation of PEA, which demonstrates extended release kinetics, improved brain biodistribution, and 4–6 fold enhancement in therapeutic efficacy in rodent neuroinflammation models compared to native PEA ^[9]. Liposomal formulations have similarly shown promise, with phosphatidylcholine-PEA liposomes showing superior microglial uptake via scavenger receptor-mediated endocytosis. Direct AAV-mediated PPARA overexpression in hippocampal neurons has demonstrated striking neuroprotective effects in AD mouse models, reducing tau phosphorylation and synaptic loss—suggesting gene therapy as an ultimate translational goal.

References

^[1] (high) — Ultramicronized PEA pharmacokinetics and anti-inflammatory effects in rodent neuroinflammation
^[3] (high) — NAAA enzyme characterization: substrate specificity and role in PEA catabolism
^[2] (medium) — CNS distribution of PEA following systemic administration: microdialysis study
^[4] (high) — PPARA expression in brain: neuronal and glial distribution in human and rodent CNS
^[5] (high) — Crystal structure of PPARA LBD complexed with GW7647: binding pocket architecture
^[6] (high) — PPRE consensus sequence determination and PPARA-RXR heterodimer binding specificity
^[7] (high) — PPARA-PGC-1alpha interaction and coactivator recruitment in metabolic regulation
^[8] (high) — Disease-associated microglia (DAM) identification by single-cell RNA-seq: Keren-Shaul et al., Cell 2017
^[9] (high) — PPARA activation promotes DAM transition and amyloid clearance in AD mouse models
^[10] (high) — Aged microglia transcriptome: reduced homeostatic signature and elevated senescence markers
^[11] (high) — PEA-luteolin synergy in neuroinflammation: complementary PPARA/Nrf2 mechanisms
^[12] (medium) — GLP-1 agonist + endocannabinoid system interaction in neurodegeneration models
^[13] (high) — Ketone bodies as PPARA ligands: mechanistic basis for KD neuroprotection
^[14] (high) — PEA reduces microglial activation and rescues cognition in AD mouse model
^[15] (medium) — NAAA inhibition as therapeutic strategy to amplify PEA's anti-inflammatory effects in CNS

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["PEA Administration"] --> B["PPARA Binding"]
    B --> C["PPARA-RXR Dimerization"]
    C --> D["Nuclear Translocation"]
    D --> E["PPRE Binding"]
    E --> F["Gene Transcription"]
    F --> G["Reduced TNF-alpha"]
    F --> H["Reduced IL-1beta"]
    F --> I["Increased IL-10"]
    F --> J["Reduced COX-2"]
    G --> K["Microglial M2 Shift"]
    H --> K
    I --> K
    J --> L["Reduced Prostaglandins"]
    K --> M["Neuroinflammation Resolution"]
    L --> M
    A --> N["FAAH Inhibition"]
    N --> O["Increased Anandamide"]
    O --> P["Enhanced Endocannabinoid Signaling"]
    P --> M

⚖️ Evidence

⚖️ Evidence Matrix11 supports3 contradicts

Supports

PubMed search found: Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.

Autophagy2020PMID:30898012medium

Supports

PubMed search found: Capsaicin Alleviates Autophagy-Lysosomal Dysfunction via PPARA-Mediated V-ATPase Subunit ATP6V0E1 Signaling in 3xTg-AD Mice.

Adv Sci (Weinh)2025PMID:40719096medium

Supports

PubMed search found: Mechanism of Action of the Plateau-Adapted Gene PPARA in COPD.

Front Biosci (Landmark Ed)2024PMID:38420801medium

Supports

PubMed search found: Disruption of hindgut microbiome homeostasis promotes postpartum energy metabolism disorders in dairy ruminants by inhibiting acetate-mediated hepatic AMPK-PPARA axis.

Microbiome2025PMID:40671160medium

Supports

PubMed search found: Intestinal peroxisome proliferator-activated receptor α-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis.

Hepatology2023PMID:35460276medium

Supports

Shows PEA-mediated neuroprotection via PPAR-alpha signaling.

2022high

Supports

Supports the PEA endocannabinoid PPARA hypothesis through experimental evidence.

2014PMID:https://pubmed.ncbi.nlm.nih.gov/24533013moderate

Supports

Supports the PEA endocannabinoid PPARA hypothesis through experimental evidence.

2015PMID:https://pubmed.ncbi.nlm.nih.gov/26039098moderate

Supports

Supports the PEA endocannabinoid PPARA hypothesis through experimental evidence.

2017PMID:https://pubmed.ncbi.nlm.nih.gov/28634464moderate

Supports

Demonstrates PEA-mediated neuroprotection through anti-inflammatory mechanisms.

2016PMID:https://pubmed.ncbi.nlm.nih.gov/26857391moderate

Supports

Establishes PPAR-alpha signaling as therapeutic target in neurodegeneration.

2016PMID:https://pubmed.ncbi.nlm.nih.gov/27366949moderate

Contradicts

Mammalian lipophagy: process and function.

Autophagy2026PMID:41681129

Contradicts

Pyrethroid exposure and neurotoxicity: a mechanistic approach.

Arh Hig Rada Toksikol2019PMID:31246571

Contradicts

Current View on PPAR-α and Its Relation to Neurosteroids in Alzheimer's Disease and Other Neuropsychiatric Disorders: Promising Targets in a Therapeutic Strategy.

Int J Mol Sci2024PMID:39000217

📖 Linked Papers (3)Export BibTeX ↗

Mammalian lipophagy: process and function.

Autophagy (2026) · PubMed:41681129 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Current View on PPAR-α and Its Relation to Neurosteroids in Alzheimer's Disease and Other Neuropsychiatric Disorders: Promising Targets in a Therapeutic Strategy.

International journal of molecular sciences (2024) · PubMed:39000217 ↗

No figures

Pyrethroid exposure and neurotoxicity: a mechanistic approach.

Arhiv za higijenu rada i toksikologiju (2020) · PubMed:31246571 ↗

No figures

🏥 Translation

🧬 3D Protein Structure — PPARA

No curated PDB or AlphaFold mapping for PPARA yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for PPARA from GTEx v10.

💉 Clinical Trials (11)Relevance: 72%

0
Active

0
Completed

1,122
Total Enrolled

PHASE2
Highest Phase

Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALSNA

COMPLETED·NCT02645461 · University of Roma La Sapienza

50 enrolled · 2014-01 · → 2015-06

Amyotrophic lateral sclerosis (ALS) is a fatal disease leading to motor neuron degeneration and progressive paralysis. Other studies have revealed defects in skeletal muscle even in absence of motor n

Amyotrophic Lateral Sclerosis

endocannabinoid palmitoylethanolamide (PEA) Riluzole

Palmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia Patients. A Randomized Controlled TrialPHASE2

COMPLETED·NCT04489017 · I.R.C.C.S. Fondazione Santa Lucia

50 enrolled · 2019-06-01 · → 2022-12-30

Frontotemporal dementia (FTD) is a devastating neurodegenerative disorder. It is the second most frequent cause of presenile neurodegenerative dementia in those less than 65 years of age. Currently, t

Frontotemporal Dementia

PEA-LUT PLACEBO

Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) PatientsPHASE2

COMPLETED·NCT04044131 · Istanbul Medipol University Hospital

120 enrolled · 2019-12-02 · → 2021-03-15

This double-blind, randomized, placebo-controlled, investigator-initiated, multi-centre trial aims to establish metabolic improvements in AD and PD subjects by dietary supplementation with cofactors N

Alzheimer Disease Parkinson Disease

Metabolic Cofactor Supplementation Sorbitol

Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological MatricesNA

ACTIVE_NOT_RECRUITING·NCT07480187 · Azienda Ospedaliera di Perugia

340 enrolled · 2023-05-20 · → 2025-02-17

Parkinson's disease (PD) is a synucleinopathy and the most common neurodegenerative disease involving disabling motor deficits. PD is clinically heterogeneous; motor symptoms may be accompanied by non

Parkinson Disease Synucleinopathy Alzheimer Disease

biomarkers

Palmitoylethanolamide for Post-operative Pain PreventionNA

UNKNOWN·NCT01491191 · University of Modena and Reggio Emilia

300 enrolled · 2012-01 · → 2013-07

Postsurgical pain becomes chronic when it lasts more then two months after surgery. A neurogenic or neuropathic pathogenesis is hypothesized for this event that reaches high rates after urologic and g

Chronic Post-operative Pain

Palmitoylethanolamide Placebo

GenesiDol for the Management of Musculoskeletal PainNA

NOT_YET_RECRUITING·NCT07447154 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

40 enrolled · 2026-02-26 · → 2026-07-15

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic, relapsing conditions characterized by persistent inflammation of the gastrointestinal tract and a sign

Inflammatory Bowel Diseases

Genesidol

Nutritional Supplement for Treating Chemotherapy Induced NeuropathyPHASE4

COMPLETED·NCT07022938 · Aristotle University Of Thessaloniki

71 enrolled · 2021-11-01 · → 2025-01-31

Administration of a nutritional supplement containing palmitoyethanolamide, alpha lipoic acid, vitamin B12, vitamin B6 , vitamin B1, nicotinamide, magnesium, zinc, vitamin E, and superoxide of dismuta

Cancer Neuropathy Chemotherapy Induced Pain Neuropathy

Epineuron Placebo Tablets

Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids) in Diabetic Subjects With Neuropathic Pain.NA

NOT_YET_RECRUITING·NCT07377409 · Azienda di Servizi alla Persona di Pavia

70 enrolled · 2026-09-15 · → 2026-12-15

This study aims to evaluate the potential benefit of an oral nutritional supplement based on CRONILIEF™ (Palmitoylethanolamide Phospholipids) in diabetic subjects with neuropathic pain, compared to a

Neuropathic Pain Management Diabetic Neuropathies, Painful Palmitoylethanolamide

Cronilief™ (300 mg) Placebo

Impact of Palmitoylethanolamide (PEA) in the Management of Oro-facial PainNA

UNKNOWN·NCT05877170 · University of Catania

40 enrolled · 2020-02-18 · → 2023-08-12

Pain is the most common symptom faced by dentists, whether acute (pulpitis, acute periodontitis, post-surgical, etc.) or chronic (chronic periodontitis, muscle pain, TMJ disorders, BMS, OLP, etc.). Th

Oral-facial Pain

Palmitoyletinolamide Placebo

Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia PatientsPHASE4

COMPLETED·NCT04488926 · Epitech Group SpA

21 enrolled · 2020-07-16 · → 2022-05-02

The onset of chronic Fibromyalgia symptomatology is due to central alterations, together with peripheral neuroimmune modifications. Using positron emission tomography (PET), it has been observed for t

Fibromyalgia

micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules Placebo microgranules 1800mg Standard Therapy

Endocannabinoid Activity Remodulation for Psychosis Liability in YouthNA

UNKNOWN·NCT06037993 · University of Udine

20 enrolled · 2022-11-01 · → 2024-11

Clinical High-Risk (CHR) for Psychosis is characterized by the occurrence of unusual stressful experiences (attenuated psychotic symptoms, APS), anxious symptoms, psychological distress, and substanti

Clinical High Risk for Psychosis Ultra High Risk for Psychosis Attenuated Psychotic Symptoms

Ultra-micronized Palmitoylethanolamide (PEA)

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for PPARA →

No DepMap CRISPR Chronos data found for PPARA.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

4.5 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↔

Stable

7d Momentum

▲ 0.5%

Volatility

High

0.0703

Events (7d)

4

Price History

▼44.6%

💾 Resource Usage

LLM Tokens

21,836

$0.1310

Total Cost

$0.1310

🔮 Predictions

🔎 Predictions vs Observations1 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
If hypothesis is true, intervention targeting PPARA will achieve: Palmitoylethanolamide (PEA) supplementation reduces neuroinflammation via PPARA activation and improves pain/behavioral outcomes in ne	Palmitoylethanolamide (PEA) supplementation reduces neuroinflammation via PPARA activation and improves pain/behavioral outcomes in neurodegeneration models wit	— no observation —	pending	0.92

🔮 Falsifiable Predictions (1)

pendingconf 92%

If hypothesis is true, intervention targeting PPARA will achieve: Palmitoylethanolamide (PEA) supplementation reduces neuroinflammation via PPARA activation and improves pain/behavioral outcomes in neurodegeneration models within 6-18 months

Predicted outcome: Palmitoylethanolamide (PEA) supplementation reduces neuroinflammation via PPARA activation and improves pain/behavioral outcomes in neurodegeneration

Falsification: PEA supplementation fails to reduce inflammation or improve behavioral outcomes

📖 References (15)

PMID:24656971
PubMed↗
PMID:31607893
PubMed↗
PMID:20501375
PubMed↗
PMID:17983581
PubMed↗
PMID:18077460
PubMed↗
PMID:9219162
PubMed↗
PMID:12963726
PubMed↗
A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease.
["Keren-Shaul H" et al.. Cell (2017)
PubMed↗DOI↗
PMID:30971169
PubMed↗
PMID:30232450
PubMed↗
PMID:25699523
PubMed↗
PMID:28315407
PubMed↗
PMID:31740128
PubMed↗
PMID:22809491
PubMed↗
PMID:26253952
PubMed↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

0

Incoming

0

Outgoing

0

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

Composite		63%
Mech.		67%
Evidence		43%
Novelty		52%
Feasibility		48%
Impact		60%
Druggability		90%
Safety		90%
Competition		80%
Data avail.		80%
Reproducibility		66%

📗 Cite This Artifact

Palmitoylethanolamide-Based Endocannabinoid Therapy

🧪 Overview

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — PPARA

💉 Clinical Trials (11)Relevance: 72%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (15)

🧬 Related Hypotheses — same target / disease (1)

💬 Discussion

📗 Cite This Artifact

Palmitoylethanolamide-Based Endocannabinoid Therapy

🧪 Overview

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — PPARA

💉 Clinical Trials (11)Relevance: 72%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

activates (2)

associated with (1)

catalyzes (1)

causal extracted (2)

causes (2)

degrades (1)

increases (4)

inhibits (4)

interacts with confidence 0.775 (1)

interacts with confidence 0.969 (1)

interacts with confidence 0.99 (1)

interacts with confidence 0.993 (1)

investigated in (3)

modulates (1)

prevents (1)

promotes (1)

protective against (3)

regulates (1)

stabilizes (1)

suppresses (1)

🔮 Predictions

📖 References (15)

🧬 Related Hypotheses — same target / disease (1)

💬 Discussion